These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 9269233)

  • 1. British HIV Association guidelines for antiretroviral treatment of HIV Seropositive individuals.
    Harindra V
    Lancet; 1997 Jun; 349(9068):1838. PubMed ID: 9269233
    [No Abstract]   [Full Text] [Related]  

  • 2. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals.
    Carey PB; Lloyd J; Timmins D
    Lancet; 1997 Jun; 349(9068):1837. PubMed ID: 9269231
    [No Abstract]   [Full Text] [Related]  

  • 3. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals.
    Brettle RP; Burns SB; Povey S; Leen CL; Welsby PD
    Lancet; 1997 Jun; 349(9068):1837-8. PubMed ID: 9269232
    [No Abstract]   [Full Text] [Related]  

  • 4. Discordant immunological response in HIV-positive patients on non-nucleoside reverse transcriptase inhibitor-based regimens.
    Ripamonti D; Arici C; Maggiolo F; Finazzi MG; Suter F
    AIDS; 2002 Jan; 16(1):130-1. PubMed ID: 11741174
    [No Abstract]   [Full Text] [Related]  

  • 5. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals.
    Payne N
    Lancet; 1997 Jun; 349(9068):1837; author reply 1838-9. PubMed ID: 9269230
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunological and virological effects of highly active antiretroviral therapy in two HIV-1 infected children.
    Leon JA; Leal M; Lissen E; Gurbindo D; Muñoz-Fernández MA
    Acta Paediatr; 2000 Mar; 89(3):373-4. PubMed ID: 10772297
    [No Abstract]   [Full Text] [Related]  

  • 7. Rapid plasma virus and CD4+ T-cell turnover in HIV-1 infection: evidence for an only transient interruption by treatment.
    Stellbrink HJ; Zöller B; Fenner T; Lichtenberg G; van Lunzen J; Albrecht H; Thiele HG; Greten H
    AIDS; 1996 Jul; 10(8):849-57. PubMed ID: 8828742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [HIV-positive: what to do?].
    Stellbrink HJ
    MMW Fortschr Med; 2011 May; 153(18):27-9. PubMed ID: 21604589
    [No Abstract]   [Full Text] [Related]  

  • 9. Does alcohol intake affect highly active antiretroviral therapy (HAART) response in HIV-positive patients?
    Fabris P; Tositti G; Manfrin V; Giordani MT; Vaglia A; Cattelan AM; Carlotto A
    J Acquir Immune Defic Syndr; 2000 Sep; 25(1):92-3. PubMed ID: 11064510
    [No Abstract]   [Full Text] [Related]  

  • 10. Progressive multifocal leukoencephalopathy following initiation of highly active antiretroviral therapy.
    Mayo J; Collazos J; Martínez E
    AIDS; 1998 Sep; 12(13):1720-2. PubMed ID: 9764796
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of highly active anti-retroviral therapy on CD3+/CD4+/CD8+ T lymphocyte counts in HIV seropositive Kashmiri patients: a follow up study.
    Shah ZA; Rasool R; Siddiqi MA
    Indian J Pathol Microbiol; 2007 Jul; 50(3):648-51. PubMed ID: 17883172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. British HIV Association guidelines for antiretroviral treatment of HIV-2-positive individuals 2010.
    Gilleece Y; Chadwick DR; Breuer J; Hawkins D; Smit E; McCrae LX; Pillay D; Smith N; Anderson J;
    HIV Med; 2010 Nov; 11(10):611-9. PubMed ID: 20961377
    [No Abstract]   [Full Text] [Related]  

  • 13. No influence of the P-glycoprotein polymorphisms MDR1 G2677T/A and C3435T on the virological and immunological response in treatment naïve HIV-positive patients.
    Winzer R; Langmann P; Zilly M; Tollmann F; Schubert J; Klinker H; Weissbrich B
    Ann Clin Microbiol Antimicrob; 2005 Jan; 4():3. PubMed ID: 15659247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [HIV-naive patients respond to pegylated interferon].
    Internist (Berl); 2003 Jun; 44(6):672. PubMed ID: 14733245
    [No Abstract]   [Full Text] [Related]  

  • 15. Evolving controversies and challenges in the management of opportunistic infections in HIV-seropositive individuals.
    Dockrell DH; Edwards S; Fisher M; Williams I; Nelson M
    J Infect; 2011 Sep; 63(3):177-86. PubMed ID: 21664932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial.
    Hurwitz BE; Klaus JR; Llabre MM; Gonzalez A; Lawrence PJ; Maher KJ; Greeson JM; Baum MK; Shor-Posner G; Skyler JS; Schneiderman N
    Arch Intern Med; 2007 Jan; 167(2):148-54. PubMed ID: 17242315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Writing Committee.
    Gazzard B; Moyle G
    Lancet; 1998 Jul; 352(9124):314-6. PubMed ID: 9690427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological and virological activity of zalcitabine and zidovudine in combination in HIV-positive people with CD4 cell counts of between 200-500 cells/mm3.
    Ibáñez A; Peraire J; Arnó A; Gutiérrez C; Cervantes M; Colomer J; Villalonga C; Camafort M; Ruiz L; Balaguer M; Vidal F; Richart C; Clotet B
    Antivir Ther; 1997 Apr; 2(2):105-11. PubMed ID: 11322274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple-drug antiretroviral therapy reports good HIV suppression in recent seroconverters.
    AIDS Patient Care STDS; 1996 Dec; 10(6):376-7. PubMed ID: 11361561
    [No Abstract]   [Full Text] [Related]  

  • 20. HIV therapeutics: points from the recent literature.
    Laurence J
    AIDS Read; 2003 Jul; 13(7):305, 307. PubMed ID: 12889448
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.